The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase ...

Eli Lilly’s Jaypirca (pirtobrutinib) has been shown to be superior to Johnson & Johnson (J&J) and AbbVie’s star Bruton's ...

Eli Lilly (LLY) stock in focus as its cancer drug Jaypirca hits main goal in a Phase 3 trial against Imbruvica of J&J (JNJ) ...

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or ...

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...

Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...

Eli Lilly today announced positive top-line results from the Phase III BRUIN CLL-314 clinical trial of Jaypirca ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Eli Lilly and Company (LLY) on Tuesday said that its cancer drug Jaypirca was more effective than AbbVie’s drug Imbruvica in ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly’s first-in-class non-covalent BTK inhibitor, demonstrated superior overall response rates compared to Imbruvica in ...

The analysis did not take into account data on the noncovalent BTKi pirtobrutinib (Jaypirca; Eli Lilly).